Beatriz E Adrada1, Rosalind Candelaria1, Stacy Moulder2, Alastair Thompson3,4, Peng Wei5, Gary J Whitman1, Vicente Valero6, Jennifer K Litton6, Lumarie Santiago1, Marion E Scoggins1, Tanya W Moseley7, Jason B White6, Elizabeth E Ravenberg6, Wei T Yang1, Gaiane M Rauch1. 1. Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Breast Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Breast Surgery, University of Baylor College of Medicine, Houston, Texas. 4. Lester and Sue Smith Breast Cancer, University of Baylor College of Medicine, Houston, Texas. 5. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Breast Imaging and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Heterogeneity exists in the response of triple-negative breast cancer (TNBC) to standard anthracycline (AC)/taxane-based neoadjuvant systemic therapy (NAST), with 40% to 50% of patients having a pathologic complete response (pCR) to therapy. Early assessment of the imaging response during NAST may identify a subset of TNBCs that are likely to have a pCR upon completion of treatment. The authors aimed to evaluate the performance of early ultrasound (US) after 2 cycles of neoadjuvant NAST in identifying excellent responders to NAST among patients with TNBC. METHODS: Two hundred fifteen patients with TNBC were enrolled in the ongoing ARTEMIS (A Robust TNBC Evaluation Framework to Improve Survival) clinical trial. The patients were divided into a discovery cohort (n = 107) and a validation cohort (n = 108). A receiver operating characteristic analysis with 95% confidence intervals (CIs) and a multivariate logistic regression analysis were performed to model the probability of a pCR on the basis of the tumor volume reduction (TVR) percentage by US from the baseline to after 2 cycles of AC. RESULTS: Overall, 39.3% of the patients (42 of 107) achieved a pCR. A positive predictive value (PPV) analysis identified a cutoff point of 80% TVR after 2 cycles; the pCR rate was 77% (17 of 22) in patients with a TVR ≥ 80%, and the area under the curve (AUC) was 0.84 (95% CI, 0.77-0.92; P < .0001). In the validation cohort, the pCR rate was 44%. The PPV for pCR with a TVR ≥ 80% after 2 cycles was 76% (95% CI, 55%-91%), and the AUC was 0.79 (95% CI, 0.70-0.87; P < .0001). CONCLUSIONS: The TVR percentage by US evaluation after 2 cycles of NAST may be a cost-effective early imaging biomarker for a pCR to AC/taxane-based NAST.
BACKGROUND: Heterogeneity exists in the response of triple-negative breast cancer (TNBC) to standard anthracycline (AC)/taxane-based neoadjuvant systemic therapy (NAST), with 40% to 50% of patients having a pathologic complete response (pCR) to therapy. Early assessment of the imaging response during NAST may identify a subset of TNBCs that are likely to have a pCR upon completion of treatment. The authors aimed to evaluate the performance of early ultrasound (US) after 2 cycles of neoadjuvant NAST in identifying excellent responders to NAST among patients with TNBC. METHODS: Two hundred fifteen patients with TNBC were enrolled in the ongoing ARTEMIS (A Robust TNBC Evaluation Framework to Improve Survival) clinical trial. The patients were divided into a discovery cohort (n = 107) and a validation cohort (n = 108). A receiver operating characteristic analysis with 95% confidence intervals (CIs) and a multivariate logistic regression analysis were performed to model the probability of a pCR on the basis of the tumor volume reduction (TVR) percentage by US from the baseline to after 2 cycles of AC. RESULTS: Overall, 39.3% of the patients (42 of 107) achieved a pCR. A positive predictive value (PPV) analysis identified a cutoff point of 80% TVR after 2 cycles; the pCR rate was 77% (17 of 22) in patients with a TVR ≥ 80%, and the area under the curve (AUC) was 0.84 (95% CI, 0.77-0.92; P < .0001). In the validation cohort, the pCR rate was 44%. The PPV for pCR with a TVR ≥ 80% after 2 cycles was 76% (95% CI, 55%-91%), and the AUC was 0.79 (95% CI, 0.70-0.87; P < .0001). CONCLUSIONS: The TVR percentage by US evaluation after 2 cycles of NAST may be a cost-effective early imaging biomarker for a pCR to AC/taxane-based NAST.
Authors: Jason D Keune; Donna B Jeffe; Mario Schootman; Abigail Hoffman; William E Gillanders; Rebecca L Aft Journal: Am J Surg Date: 2010-04 Impact factor: 2.565
Authors: Elizabeth A M O'Flynn; David Collins; James D'Arcy; Maria Schmidt; Nandita M de Souza Journal: Eur J Radiol Date: 2016-02-05 Impact factor: 3.528
Authors: Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz Journal: Lancet Date: 2014-02-14 Impact factor: 79.321
Authors: William M Sikov; Donald A Berry; Charles M Perou; Baljit Singh; Constance T Cirrincione; Sara M Tolaney; Charles S Kuzma; Timothy J Pluard; George Somlo; Elisa R Port; Mehra Golshan; Jennifer R Bellon; Deborah Collyar; Olwen M Hahn; Lisa A Carey; Clifford A Hudis; Eric P Winer Journal: J Clin Oncol Date: 2014-08-04 Impact factor: 44.544
Authors: M L Marinovich; F Sardanelli; S Ciatto; E Mamounas; M Brennan; P Macaskill; L Irwig; G von Minckwitz; N Houssami Journal: Breast Date: 2012-08-03 Impact factor: 4.380
Authors: Xia Li; Lori R Arlinghaus; Gregory D Ayers; A Bapsi Chakravarthy; Richard G Abramson; Vandana G Abramson; Nkiruka Atuegwu; Jaime Farley; Ingrid A Mayer; Mark C Kelley; Ingrid M Meszoely; Julie Means-Powell; Ana M Grau; Melinda Sanders; Sandeep R Bhave; Thomas E Yankeelov Journal: Magn Reson Med Date: 2013-05-09 Impact factor: 4.668
Authors: Andrew Evans; Patsy Whelehan; Alastair Thompson; Colin Purdie; Lee Jordan; Jane Macaskill; Shelley Waugh; Frances Fuller-Pace; Katrin Brauer; Sarah Vinnicombe Journal: Ultraschall Med Date: 2017-09-21 Impact factor: 6.548
Authors: Sarah L Savaridas; Yee Ting Sim; Sarah J Vinnicombe; Colin A Purdie; Alastair M Thompson; Andy Evans Journal: Cancer Imaging Date: 2019-10-21 Impact factor: 3.909